Compare OPAL & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAL | STRO |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.3M | 85.0M |
| IPO Year | N/A | 2018 |
| Metric | OPAL | STRO |
|---|---|---|
| Price | $2.18 | $11.75 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 4 | 8 |
| Target Price | $2.81 | ★ $18.29 |
| AVG Volume (30 Days) | ★ 386.4K | 103.0K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $329,243,000.00 | $105,646,000.00 |
| Revenue This Year | $17.15 | $63.08 |
| Revenue Next Year | $22.04 | N/A |
| P/E Ratio | $95.04 | ★ N/A |
| Revenue Growth | ★ 7.26 | N/A |
| 52 Week Low | $1.26 | $5.23 |
| 52 Week High | $4.08 | $21.50 |
| Indicator | OPAL | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 45.03 | 74.82 |
| Support Level | $2.12 | $10.15 |
| Resistance Level | $2.87 | $12.32 |
| Average True Range (ATR) | 0.19 | 0.85 |
| MACD | -0.03 | -0.20 |
| Stochastic Oscillator | 27.01 | 84.49 |
OPAL Fuels Inc is a fully integrated, nationwide leader in the production and distribution of low-carbon intensity renewable natural gas. The company is also engaged in the marketing and distribution of RNG to heavy-duty trucking and other hard-to-de-carbonize industrial sectors. The company designs, develops, constructs, operates, and services Fueling Stations for trucking fleets across the country that use natural gas to displace diesel as their transportation fuel. The company derives revenue from the sale of Renewable Power, design, development, construction, and service of Fueling Stations, and sales of RNG produced by OPAL and third parties as pipeline-quality natural gas.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.